Literature DB >> 11154098

Combined use of risperidone and olanzapine in the treatment of patients with resistant schizophrenia: a preliminary case series report.

V Lerner1, B Chudakova, S Kravets, I Polyakova.   

Abstract

Polypharmacy, or the use of multiple drugs in the therapy of psychiatric disorders, is not recommended. However, appropriate combinations of pharmacologic mechanisms may enhance the efficacy of antipsychotic drugs and alter the course of schizophrenia. In recent years, some articles have been published about the successful use of clozapine and risperidone in combination for the treatment of patients with resistant schizophrenic and schizoaffective disorders. However, safety of this drug combination is open to discussion. This report presents the results of a preliminary study of five patients with resistant schizophrenia successfully treated with risperidone-olanzapine combination. The results suggest that this combination may be useful. In the future, the efficacy of risperidone-olanzapine combination should be confirmed in larger study populations before its clinical application is considered.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11154098     DOI: 10.1097/00002826-200009000-00009

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  10 in total

Review 1.  Treatment-refractory schizophrenia.

Authors:  P F Buckley; L D Wiggins; S Sebastian; B Singer
Journal:  Curr Psychiatry Rep       Date:  2001-10       Impact factor: 5.285

2.  Augmentation of olanzapine in treatment-resistant schizophrenia.

Authors:  Mathias Zink
Journal:  J Psychiatry Neurosci       Date:  2005-11       Impact factor: 6.186

Review 3.  Benefits and risks of antipsychotic polypharmacy: an evidence-based review of the literature.

Authors:  Constantin Tranulis; Leila Skalli; Pierre Lalonde; Luc Nicole; Emmanuel Stip
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

4.  Concept and Management of Treatment Resistant Schizophrenia (TRS).

Authors:  Nitesh Painuly; Nitin Gupta; Ajit Avasthi
Journal:  Indian J Psychiatry       Date:  2004-04       Impact factor: 1.759

5.  [Atypical antipsychotics in therapy refractory schizophrenia].

Authors:  I Schäfer; M Lambert; D Naber
Journal:  Nervenarzt       Date:  2004-01       Impact factor: 1.214

6.  Antipsychotics prescribing patterns of patients with schizophrenia admitted to korean general hospital psychiatric unit: 2001 to 2008.

Authors:  Hye Jin Choi; Seung Ho Jung; Min Hee Kang; Jeong Seop Lee; Jae Nam Bae; Chul Eung Kim
Journal:  Clin Psychopharmacol Neurosci       Date:  2011-04-30       Impact factor: 2.582

7.  Treatment of the special patient with schizophrenia.

Authors:  R R Conley; D L Kelly
Journal:  Dialogues Clin Neurosci       Date:  2001-06       Impact factor: 5.986

8.  Treatment-refractory schizophrenia.

Authors:  Asaf Caspi; Michael Davidson; Carol A Tamminga
Journal:  Dialogues Clin Neurosci       Date:  2004-03       Impact factor: 5.986

9.  New Modified UPLC/Tandem Mass Spectrometry Method for Determination of Risperidone and Its Active Metabolite 9-Hydroxyrisperidone in Plasma: Application to Dose-Dependent Pharmacokinetic Study in Sprague-Dawley Rats.

Authors:  Essam Ezzeldin; Marwa Tammam; Nisreen F Abo Talib
Journal:  Int J Anal Chem       Date:  2017-05-03       Impact factor: 1.885

10.  Efficacy and clinical determinants of antipsychotic polypharmacy in psychotic patients experiencing an acute relapse and admitted to hospital stay: results from a cross-sectional and a subsequent longitudinal pilot study.

Authors:  Felice Iasevoli; Elisabetta F Buonaguro; Massimo Marconi; Emanuela Di Giovambattista; Maria Paola Rapagnani; Domenico De Berardis; Giovanni Martinotti; Monica Mazza; Raffaele Balletta; Nicola Serroni; Massimo Di Giannantonio; Andrea de Bartolomeis; Alessandro Valchera
Journal:  ISRN Pharmacol       Date:  2014-01-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.